These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 31104335)

  • 21. Plasma metabolomics in early Alzheimer's disease patients diagnosed with amyloid biomarker.
    Peña-Bautista C; Roca M; Hervás D; Cuevas A; López-Cuevas R; Vento M; Baquero M; García-Blanco A; Cháfer-Pericás C
    J Proteomics; 2019 May; 200():144-152. PubMed ID: 30978462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer's disease.
    Nho K; Horgusluoglu E; Kim S; Risacher SL; Kim D; Foroud T; Aisen PS; Petersen RC; Jack CR; Shaw LM; Trojanowski JQ; Weiner MW; Green RC; Toga AW; Saykin AJ;
    BMC Med Genomics; 2016 Aug; 9 Suppl 1(Suppl 1):30. PubMed ID: 27535542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer's disease.
    Teuber-Hanselmann S; Rekowski J; Vogelgsang J; von Arnim C; Reetz K; Stang A; Jöckel KH; Wiltfang J; Esselmann H; Otto M; Tumani H; Herring A; Keyvani K
    J Neurol Neurosurg Psychiatry; 2020 Jan; 91(1):40-48. PubMed ID: 31371645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
    Olsson B; Lautner R; Andreasson U; Öhrfelt A; Portelius E; Bjerke M; Hölttä M; Rosén C; Olsson C; Strobel G; Wu E; Dakin K; Petzold M; Blennow K; Zetterberg H
    Lancet Neurol; 2016 Jun; 15(7):673-684. PubMed ID: 27068280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leveraging Multilayered "Omics" Data for Atopic Dermatitis: A Road Map to Precision Medicine.
    Ghosh D; Bernstein JA; Khurana Hershey GK; Rothenberg ME; Mersha TB
    Front Immunol; 2018; 9():2727. PubMed ID: 30631320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alzheimer's disease in the omics era.
    Sancesario GM; Bernardini S
    Clin Biochem; 2018 Sep; 59():9-16. PubMed ID: 29920246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
    Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
    J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
    Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
    J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alzheimer's Disease: Genomics and Beyond.
    Song F; Han G; Bai Z; Peng X; Wang J; Lei H
    Int Rev Neurobiol; 2015; 121():1-24. PubMed ID: 26315760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Alzheimer's disease-associated risk loci on cerebrospinal fluid biomarkers and disease progression: a polygenic risk score approach.
    Martiskainen H; Helisalmi S; Viswanathan J; Kurki M; Hall A; Herukka SK; Sarajärvi T; Natunen T; Kurkinen KM; Huovinen J; Mäkinen P; Laitinen M; Koivisto AM; Mattila KM; Lehtimäki T; Remes AM; Leinonen V; Haapasalo A; Soininen H; Hiltunen M
    J Alzheimers Dis; 2015; 43(2):565-73. PubMed ID: 25096612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Knowledge-driven binning approach for rare variant association analysis: application to neuroimaging biomarkers in Alzheimer's disease.
    Kim D; Basile AO; Bang L; Horgusluoglu E; Lee S; Ritchie MD; Saykin AJ; Nho K
    BMC Med Inform Decis Mak; 2017 May; 17(Suppl 1):61. PubMed ID: 28539126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.
    Wattmo C; Blennow K; Hansson O
    BMC Neurol; 2020 Jan; 20(1):10. PubMed ID: 31918679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Vanderbilt Memory & Aging Project: Study Design and Baseline Cohort Overview.
    Jefferson AL; Gifford KA; Acosta LM; Bell SP; Donahue MJ; Davis LT; Gottlieb J; Gupta DK; Hohman TJ; Lane EM; Libon DJ; Mendes LA; Niswender K; Pechman KR; Rane S; Ruberg FL; Su YR; Zetterberg H; Liu D
    J Alzheimers Dis; 2016 Mar; 52(2):539-59. PubMed ID: 26967211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omics-based biomarkers discovery for Alzheimer's disease.
    Aerqin Q; Wang ZT; Wu KM; He XY; Dong Q; Yu JT
    Cell Mol Life Sci; 2022 Nov; 79(12):585. PubMed ID: 36348101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis.
    Meyer PF; Savard M; Poirier J; Labonté A; Rosa-Neto P; Weitz TM; Town T; Breitner J; ;
    J Alzheimers Dis; 2018; 63(2):577-590. PubMed ID: 29660934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease.
    Racine AM; Clark LR; Berman SE; Koscik RL; Mueller KD; Norton D; Nicholas CR; Blennow K; Zetterberg H; Jedynak B; Bilgel M; Carlsson CM; Christian BT; Asthana S; Johnson SC
    J Alzheimers Dis; 2016 Oct; 54(4):1395-1408. PubMed ID: 27589532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40.
    Deming Y; Black K; Carrell D; Cai Y; Del-Aguila JL; Fernandez MV; Budde J; Ma S; Saef B; Howells B; Bertelsen S; Huang KL; Sutphen CL; Tarawneh R; Fagan AM; Holtzman DM; Morris JC; Goate AM; Dougherty JD; Cruchaga C
    BMC Neurol; 2016 Nov; 16(1):217. PubMed ID: 27832767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
    Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
    Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Widely targeted metabolomics of Alzheimer's disease postmortem cerebrospinal fluid based on 9-fluorenylmethyl chloroformate derivatized ultra-high performance liquid chromatography tandem mass spectrometry.
    Muguruma Y; Tsutsui H; Noda T; Akatsu H; Inoue K
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Aug; 1091():53-66. PubMed ID: 29852382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease.
    Nho K; Kim S; Horgusluoglu E; Risacher SL; Shen L; Kim D; Lee S; Foroud T; Shaw LM; Trojanowski JQ; Aisen PS; Petersen RC; Jack CR; Weiner MW; Green RC; Toga AW; Saykin AJ;
    BMC Med Genomics; 2017 May; 10(Suppl 1):29. PubMed ID: 28589856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.